Molybdenum Cofactor Deficiency Type A (MoCoD-a) Epidemiology Market Forecasts Report 2020-2034: Focus on United States, EU4 (Germany, France, Italy, Spain), United Kingdom, and Japan - ResearchAndMarkets.com

The "Molybdenum Cofactor Deficiency Type A (MoCoD-a) - Epidemiology Forecast-2034" report has been added to ResearchAndMarkets.com's offering.

The "Molybdenum Cofactor Deficiency Type A (MoCoD-A) - Epidemiology Forecast - 2034" report delivers an in-depth understanding of Molybdenum Cofactor Deficiency Type A (MoCoD-A), historical and forecasted epidemiology of Molybdenum Cofactor Deficiency Type A (MoCoD-A) in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Key Highlights

• Due to heightened awareness, resulting in a rise in the diagnosed prevalence of MOCOD-A, analysts anticipate that the Total Prevalent Cases of Molybdenum Cofactor Deficiency Type A (MoCoD-A) in the 7MM stood at approximately 270 in 2023. These numbers are expected to continue increasing throughout the forecast period spanning from 2024 to 2034.
• It is estimated that approximately 54% of the Total Diagnosed Prevalent Cases of Molybdenum Cofactor Deficiency Type A (MoCoD-A) in the 7MM were in the United States. Our estimations indicate that in 2023, the EU4 and the UK collectively represented 36% diagnosed prevalent cases of MOCOD-A.
• According to analysis, the Total Diagnosed Prevalent Cases of MOCOD-A in the US was found to be nearly 30 in 2023 and is estimated to increase with a significant CAGR throughout the forecast period.
• As per estimates, Japan accounted for nearly 9% of the Total Diagnosed Prevalent Cases of MOCOD-A in the 7MM in 2023.

Molybdenum Cofactor Deficiency Type A (MoCoD-A) Diagnosis

Diagnosing MoCoD involves identifying biallelic pathogenic variants in GPHN, MOCS1, MOCS2, or MOCS3 genes. Alternatively, if genetic testing is unavailable, significantly reduced sulfite oxidase enzyme activity in cultured fibroblasts confirms the diagnosis. However, distinguishing between total and partial enzyme activity loss is challenging due to low sulfite oxidase expression in fibroblasts. Molecular genetic testing, which is highly sensitive, usually replaces enzymatic testing and is therefore preferred for MoCoD diagnosis.

MoCoD-A diagnosis is complex due to its rarity, vague symptoms, and the requirement for genetic confirmation. Confirming MoCoD-A involves identifying biallelic mutations in the MOCS1 gene and detecting specific metabolites in blood or urine tests. These steps necessitate specialized genetic testing and biochemical analyses.

Molybdenum Cofactor Deficiency Type A (MoCoD-A) Epidemiology

Approximately 270 Prevalent Cases of MOCOD-A were found in 2023 in the 7MM.

The United States exhibited the highest diagnosed prevalent population of MOCOD-A, as compared to other 7MM countries. As per estimations, the Total Diagnosed Prevalent Cases of MOCOD-A in the US was around 30 in 2023 and is projected to increase during the forecast period owing to the increasing awareness among the patient population.

According to estimates, the Total Diagnosed Prevalent Cases of MOCOD-A in EU4 and the UK were found to be ~20 in 2023. Throughout the study period, it is anticipated that there will be a substantial increase in cases for all contributing countries. The least proportion of MOCOD-A cases was reported in Spain among the EU4 countries.

The data indicates that Japan had the lowest number of Total Diagnosed Prevalent Cases of MOCOD-A among the 7MM in 2023, accounting for just 9% of the overall cases. However, it is projected to experience substantial growth by 2034, with a notable CAGR.

The Diagnosed Prevalence of MOCOD-A was divided into two categories: 'MoCoD Type A' and 'MoCoD Type B and Type C'. MoCoD Type A had a higher number of cases compared to MoCoD Type B and Type C, mainly because mutations in the MOCS1 gene are more prevalent than mutations in the MOCS2 or GPHN genes, which are associated with MoCoD Type B and Type C, respectively.

KOL Views

To gaze into the epidemiology insights of the real world, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate our secondary research on disease prevalence.

The analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the Children's Hospital Colorado, University of Colorado Denver, United States, University of Cologne, Germany, Department of Pediatrics, Seirei-Mikatahara General Hospital, Japan, and others were contacted. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.

Scope of the Report

• The report covers a segment of key events, an executive summary, descriptive overview of Molybdenum Cofactor Deficiency Type A (MoCoD-A), explaining its causes, signs and symptoms, and currently available diagnostic algorithms and guidelines.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and diagnosis guidelines.
• The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
• A detailed review of current challenges in establishing the diagnosis.

Molybdenum Cofactor Deficiency Type A (MoCoD-A) Report Insights

• Patient Population
• Country-wise Epidemiology Distribution
• Prevalent cases of MoCoD
• Diagnosed Prevalent Cases of MoCoD
• Type-specific Diagnosed Prevalent Cases of MoCoD

Molybdenum Cofactor Deficiency Type A (MoCoD-A) Report Key Strengths

• 11 years Forecast
• The 7MM Coverage
• Molybdenum Cofactor Deficiency Type A (MoCoD-A) Epidemiology Segmentation

Molybdenum Cofactor Deficiency Type A (MoCoD-A) Report Assessment

• Current Diagnostic Practices Patient Segmentation

Epidemiology Insights

• What are the disease risk, burdens, and unmet needs of Molybdenum Cofactor Deficiency Type A (MoCoD-A)? What will be the growth opportunities across the 7MM concerning the patient population of Molybdenum Cofactor Deficiency Type A (MoCoD-A)?
• What is the historical and forecasted Molybdenum Cofactor Deficiency Type A (MoCoD-A) patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• Why is the diagnosed prevalent cases of MOCOD-A in Japan lower than the US?
• Which country has a high patient share for MOCOD-A? 

Key Topics Covered:

1. Key Insights

2. Report Introduction

3. MOCOD-A Epidemiology Overview at a Glance

3.1. Patient Share (%) Distribution of MOCOD-A in 2020

3.2. Patient Share (%) Distribution of MOCOD-A in 2034

4. Methodology of MOCOD-A Epidemiology

5. Executive Summary of MOCOD-A

6. Key Events

7. Disease Background and Overview

7.1. Introduction

7.2. Types of MoCoD

7.3. Clinical Manifestations

7.4. Signs and Symptoms

7.5. Risk Factors

7.6. Genetics and Inheritance

7.7. Pathogenesis

7.8. Prognosis

7.9. Staging

7.10. Diagnosis

7.10.1. Diagnostic criteria

7.10.2. Differential diagnosis

8. Epidemiology and Patient Population

8.1. Key Findings

8.2. Assumptions and Rationale: The 7MM

8.2.1. Prevalent cases of MoCoD

8.2.2. Diagnosed Prevalent Cases of MoCoD

8.2.3. Type-specific Diagnosed Prevalent Cases of MoCoD

8.3. Total Diagnosed Prevalent Cases of MOCOD-A in the 7MM

8.4. The US

8.4.1. Prevalent cases of MoCoD

8.4.2. Diagnosed Prevalent Cases of MoCoD

8.4.3. Type-specific Diagnosed Prevalent Cases of MoCoD

8.5. The EU4 and the UK

8.5.1. Germany

8.5.2. France

8.5.3. Italy

8.5.4. Spain

8.5.5. The UK

8.6. Japan

9. Patient Journey

10. KOL Views

11. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/91se4i

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250311348750/en/